[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488578":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":68,"centralContacts":69,"locations":75,"responsibleParty":93,"collaborators":97,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":68,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":68,"enrollmentInfo":110,"targetDuration":68,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":68,"overallStatus":78,"whyStopped":68,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Thomas Jefferson University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (CEUS with MRI\u002FCT)","EXPERIMENTAL","Patients receive Lumason IV and undergo CEUS imaging with MRI\u002FCT on study. Patients' electronic medical record is reviewed every 6 months throughout study.",[13,14,15,16,17],"Drug: Sulfur Hexafluoride Lipid Microspheres","Procedure: Contrast-Enhanced Ultrasound","Procedure: Computed Tomography","Procedure: Magnetic Resonance Imaging","Other: Electronic Health Record Review",[19,28,35,48,64],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Sulfur Hexafluoride Lipid Microspheres","Given IV",[9],[25,26,27],"Lumason","SF6 Lipid Microspheres","Sulfur Hexafluoride Lipid-type A Microspheres",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"PROCEDURE","Contrast-Enhanced Ultrasound","Undergo CEUS",[9],[34],"CEUS",{"type":29,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Computed Tomography","Undergo CT",[9],[40,41,42,43,44,45,46,47],"CAT","CAT Scan","Computed Axial Tomography","computerized axial tomography","Computerized Tomography","CT","CT SCAN","tomography",{"type":29,"name":49,"description":50,"armGroupLabels":51,"otherNames":52},"Magnetic Resonance Imaging","Undergo MRI",[9],[53,54,55,56,57,58,59,60,61,62,63],"Magnetic Resonance","Magnetic Resonance Imaging Scan","Medical Imaging","Magnetic Resonance \u002F Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","NMR Imaging","NMRI","nuclear magnetic resonance imaging",{"type":6,"name":65,"description":66,"armGroupLabels":67,"otherNames":68},"Electronic Health Record Review","Review electronic medical record",[9],null,[70],{"name":71,"role":72,"phone":73,"phoneExt":68,"email":74},"John Eisenbrey, PhD","CONTACT","215-503-5188","john.eisenbrey@jefferson.edu",[76],{"facility":77,"status":78,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":90},"Sidney Kimmel Cancer Center at Thomas Jefferson University","RECRUITING","Philadelphia","Pennsylvania","19107","United States","US",{"type":85,"coordinates":86},"Point",[87,88],-75.16362,39.95238,{"lat":88,"lon":87},[91],{"name":92,"role":72,"phone":68,"phoneExt":68,"email":74},"John Eisenbrey, MD",{"type":94,"investigatorFullName":95,"investigatorTitle":96,"investigatorAffiliation":5,"oldNameTitle":68,"oldOrganization":68},"SPONSOR_INVESTIGATOR","john eisenbrey","Associate Professor, Radiology",[98],{"name":99,"class":100},"National Cancer Institute (NCI)","NIH","100488578","phase-2-contrast-enhanced-ultrasound-imaging-for-diagnosing-recurrent-renal-cell-carcinoma-rcc-post-ablation-100488578",false,"NCT05641935","Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation","Multi-Modality Detection of RCC Recurrence Post Ablation","Inclusion Criteria:\n\n* Previously received cryotherapy or microwave therapy of RCC\n* Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy\n* Have previously had or are scheduled to have a contrast-enhanced MRI\u002FCT for the monitoring of RCC recurrence within 4 weeks of the CEUS study\n* Be at least 18 years of age\n* Be medically stable\n* If a female of child-bearing age, must have a negative pregnancy test\n* Have signed Informed Consent to participate in the study\n\nExclusion Criteria:\n\n* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable\n* Patients with known sensitivities to the components of Lumason","ALL","18 Years",{"count":111,"type":112},210,"ESTIMATED","INTERVENTIONAL",[115],"PHASE2","This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.",[118,119],"Recurrent Renal Cell Carcinoma","Renal Cell Carcinoma","2026-02-12",{"date":122,"type":123},"2026-02-17","ACTUAL",{"date":125,"type":123},"2022-11-03",{"date":127,"type":112},"2027-08-31",{"name":95,"class":6},1]